Wodwala Woyamba Kumwedwa Ndi New Therapy for Advanced Hepatocellular Carcinoma

Kintor Pharmaceutical Limited lero yalengeza za kuyezetsa koyamba kwa odwala ku United States kwa chipatala cha Multi-regional phase II (NCT05178043) cha antibody ya ALK-1 (GT90001) ndi Nivolumab (Opdivo) yochizira advanced Hepatocellular Carcinoma (HCC) pa Meyi 2, 2022.

Malinga ndi Global Cancer Statistics 2020, khansa yoyamba ya chiwindi ndi khansa yachisanu ndi chimodzi yomwe imapezeka kawirikawiri komanso yachitatu yomwe imayambitsa kufa kwa khansa padziko lonse lapansi, ndi pafupifupi 906,000 odwala atsopano ndi 830,000 afa [1]. HCC ndi mtundu wofala kwambiri wa khansa ya m'chiwindi mwa akuluakulu, yomwe imakhala pafupifupi 75% -85% ya khansa zonse za chiwindi. [2] Ponseponse, chithandizo cha khansa ya chiwindi ndizovuta, ndipo kupulumuka kwa khansa ya chiwindi kuyenera kukonzedwanso ndi njira zabwino zothandizira.

M'zaka zaposachedwa, njira zochiritsira zatsopano zawonjezera zosankha za odwala omwe ali ndi khansa yachiwindi yapamwamba. Mu 2020, mankhwala ophatikiza a Atezolizumab (TECENTRIQ®) ndi Bevacizumab (AVASTIN®) (“T+A”) adavomerezedwa ku US kuti alowe m'malo mwa Sorafenib (NEXAVAR®) kapena Lenvatinib (LENVIMA®) ngati muyezo woyamba wa chisamaliro ("SOC") kwa HCC yapamwamba, kutsatira ndi kuvomerezedwa m'maiko ena ambiri ndi zigawo. Pakhala pali zosowekera zazikulu zosakwaniritsidwa za chithandizo chachiwiri kwa odwala omwe adalephera kulandira chithandizo ndi T+A kapena osalekerera.

Dr. Tong Youzhi, woyambitsa, Wapampando, ndi CEO wa Kintor Pharma, anati, "Ndife okondwa kumaliza mlingo woyamba wa odwala mu gawo lachiwiri la mayesero achipatala a GT90001 ophatikizana ndi Nivolumab pochiza HCC yapamwamba. Tikuyembekeza kuti kafukufuku wa gawo lachiwiri la MRCT ayika GT90001 ngati wophatikiza ndi I/O pamankhwala achiwiri a HCC. Tikusankhanso njira zamankhwala za GT90001 mu zotupa zina zolimba ndipo tikuyembekeza kubweretsa njira zatsopano zothandizira odwala omwe ali ndi zosowa zosakwanira.